Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Thailand Inflation Remains Negative for 10th Straight Month in January 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
